Tracking Utilization of Neoadjuvant Endocrine Therapy (NET) and Neoadjuvant Chemotherapy (NCT) for Hormone Receptor-Positive Breast Cancer (HR + BC) in the U.S.A. Over Time – A TriNetX Database Study
Clinical Breast Cancer · 2026-07 · 26 (7) · 39-45
DOI: 10.1016/j.clbc.2026.05.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2026-07. Verfasst von Jubin K Lim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Methodist Healthcare System, San Antonio, TX. Electronic address: jubin.lim@mhshealth.com. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Breast Neoplasms, Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Methodist Healthcare System, San Antonio, TX. Electronic address: jubin.lim@mhshealth.com.
- Department of Surgery, Virginia Commonwealth University, Richmond, VA.
- Biostatistics Shared Resource, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA.
- Department of Internal Medicine, Medical University of South Carolina at Charleston, Charleston, SC.
- Division of Surgical Oncology, Departments of Surgery and Microbiology & Immunology and the Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA.
Zitieren
APA
Lim, J. K., Gibson, A. E., He, J., Antonucci, A., & Bear, H. D. (2026). Tracking Utilization of Neoadjuvant Endocrine Therapy (NET) and Neoadjuvant Chemotherapy (NCT) for Hormone Receptor-Positive Breast Cancer (HR + BC) in the U.S.A. Over Time – A TriNetX Database Study. Clinical Breast Cancer, 26(7), 39-45. https://doi.org/10.1016/j.clbc.2026.05.008
Vancouver
Lim JK, Gibson AE, He J, Antonucci A, Bear HD. Tracking Utilization of Neoadjuvant Endocrine Therapy (NET) and Neoadjuvant Chemotherapy (NCT) for Hormone Receptor-Positive Breast Cancer (HR + BC) in the U.S.A. Over Time – A TriNetX Database Study. Clinical Breast Cancer. 2026;26(7):39-45. doi:10.1016/j.clbc.2026.05.008
BibTeX
@article{Lim2026,
author = {Lim, Jubin K and Gibson, Anna E and He, Jian and Antonucci, Alexis and Bear, Harry D},
title = {Tracking Utilization of Neoadjuvant Endocrine Therapy (NET) and Neoadjuvant Chemotherapy (NCT) for Hormone Receptor-Positive Breast Cancer (HR + BC) in the U.S.A. Over Time – A TriNetX Database Study},
journal = {Clinical Breast Cancer},
year = {2026},
volume = {26},
number = {7},
pages = {39--45},
doi = {10.1016/j.clbc.2026.05.008}
}
EUVIMED